# An Open Label Trial Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetic Profile of Tacrolimus Inhalation Powder in Adult Lung Transplant Recipients

> **NCT05501574** · PHASE2 · TERMINATED · sponsor: **TFF Pharmaceuticals, Inc.** · enrollment: 14 (actual)

## Conditions studied

- Lung Transplant Rejection

## Interventions

- **DRUG:** Tacrolimus Inhalation Powder
- **DEVICE:** Plastiape RS00 Dry Powder inhaler device

## Key facts

- **NCT ID:** NCT05501574
- **Lead sponsor:** TFF Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-04-18
- **Primary completion:** 2024-10-29
- **Final completion:** 2024-12-23
- **Target enrollment:** 14 (ACTUAL)
- **Why stopped:** Study was terminated due to funding constraints
- **Last updated:** 2025-01-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05501574

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05501574, "An Open Label Trial Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetic Profile of Tacrolimus Inhalation Powder in Adult Lung Transplant Recipients". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT05501574. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*